Trisomy 12 in chronic lymphocytic leukemia: an interphase cytogenetic study
نویسندگان
چکیده
منابع مشابه
Trisomy 12 in chronic lymphocytic leukemia: an interphase cytogenetic study.
Interphase cytogenetics by means of in situ hybridization with the chromosome 12-specific biotinylated alpha satellite DNA probe pSP 12-1 was used for the study of trisomy 12, the most common chromosomal abnormality in chronic lymphocytic leukemia. In situ hybridization was performed on methanol/acetic acid fixed cells of conventional cytogenetic preparations from eight patients and on morpholo...
متن کاملFluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia.
Cytogenetic studies (CG) of 475 chronic lymphocytic leukemia (CLL) cases showed trisomy 12 in 6.1% or 26% of patients with abnormal karyotypes. Fluorescence in situ hybridization (FISH) detected trisomy 12 in 35% of 117 CLL patients. Only 34.6% of cases detected by FISH were detected by CG. Twelve patients had low levels of trisomic cells (4% to 11%) relative to clonal B cells (47.5% to 86%), s...
متن کاملMolecular cytogenetic lesions in chronic lymphocytic leukemia
In the 90’s, only approximately 50% of chronic lymphocytic leukemia (CLL) could be shown to carry a chromosome defect, a figure reflecting inadequate cell division. The introduction of FISH allowed for the detection of chromosome aberrations in 80% of the cases and every patient could be included in a specific group according to a hierarchical cytogenetic classification as follows: 17p> 11q> +1...
متن کاملInterphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Select cytogenetic abnormalities such as del(17)(p13.1) and del(11)(q22-q23)predict rapid disease progression and inferior survival in chronic lymphocytic leukemia (CLL). We sought to determine the impact of the four most common interphase cytogenetic abnormalities in 28 CLL patients relative to response to three-times-a-week rituximab therapy. Abnormalities were noted in 25 of the 28 patients ...
متن کاملObinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12
Obinutuzumab, an afucosylated, type 2 anti-CD20 antibody, showed superior results to rituximab in a head-to-head comparison in combination with chlorambucil in the first-line treatment of chronic lymphocytic leukaemia (CLL) patients with comorbidities in the CLL11 trial (NCT01010061). Enhanced activity of obinutuzumab in this setting may reflect better binding to Fc receptors as well as the dir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1991
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v78.3.775.775